Outcome of the Board Meeting held on Wednesday, November 12, 2025, i.e, today, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs reported unaudited results for Q2 FY26 with revenue from operations of Rs 131.85 lakhs (up from Rs 17.13 lakhs in Q2 FY25) and profit for the quarter of Rs 2.44 lakhs versus a loss of Rs 30.44 lakhs a year ago. For H1 FY26, total revenue jumped to Rs 252.87 lakhs from Rs 30.53 lakhs in H1 FY25, with the company swinging to a profit of Rs 6.18 lakhs from a loss of Rs 29.36 lakhs. The auditor (PPKG & Co) issued an unmodified limited review conclusion. The Board also approved financial statements as on September 30, 2025 for the purpose of the proposed amalgamation with Hatri Pharma Private Limited at a 1:1 share swap ratio, where Hatri Pharma has a net worth of Rs 1,610 lakhs and turnover of Rs 1,846.41 lakhs versus Venmax's Rs 857.72 lakhs and Rs 252.87 lakhs respectively.
Sharp top-line growth and a return to profitability are positive signals for shareholders, suggesting improved business traction. However, operating cash flow remained deeply negative at Rs (402.06) lakhs in H1 FY26, indicating the profit is not yet backed by cash generation and working capital is stretching, which investors should watch closely.